BioStem Technologies Inc. logo

BioStem Technologies Inc.

BSEM | NASDAQ
Chart Builder DCF Calculator
$1.22
+$0.10 (+8.93%)
Nov 2, 2026, 12:15 PM ET · Market open

Company Profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Key Executives

Name Position
Jason Matuszewski Chief Executive Officer, President, Secretary & Chairman
Andrew Vanvurst Chief Operating Officer & Director
Brandon Poe Chief Financial Officer
Barry J. Hassett Chief Commercial Officer
David Woynarowski Chief Medical Officer
Irmgard Huber International Medical Advisor & Interim Chief Medical Officer
Jeff Humke Vice President of Human Resources
Katherine Gorrell Chief Legal & Compliance Officer
Larry Jones Chief Revenue Officer
Michael Fortunato Chief Accounting Officer
Noah Agron Vice President of Corporate Finance & Strategy

Latest SEC Filings

Date Type Title
Oct 02, 2026 S-1 Filing
Sep 30, 2026 8-K Current Report
Sep 29, 2026 EFFECT Filing
Sep 29, 2026 424B3 Filing
Sep 21, 2026 D Filing
Sep 18, 2026 S-1 Filing
Sep 18, 2026 8-K Current Report
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 17, 2026 4 Filing
View All SEC Filings ➞
BioStem Technologies Inc.
BioStem Technologies Inc. logo
Country United States
IPO Date Mar 17, 2015
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Jason Matuszewski

Contact Details

4901 Northwest 17th Way Fort Lauderdale, Florida 33309 United States

Stock Details

Ticker Symbol BSEM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001658678
CUSIP Number 090684200
ISIN Number US0906842002
SIC Code

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.